Europe / Sandoz Bolsters its Essential Medicine Manufacturing Capacity
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Austria GmbH
Stella-Klein-Löw-Weg 15/3
1020 Vienna
Austria
Phone: +43 1 484 4613
Fax: +43 1 484 4613 11
www.biogenidec.at
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian affiliate being chosen as lead office for CEE and the company’s life sciences and…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore,…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations.…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays…
See our Cookie Privacy Policy Here